MARKETS / NYSE / PHG

NYSE · X-RAY APPARATUS & TUBES & RELATED IRRADIATION APPARATUS · LARGE CAP

Koninklijke Philips NV PHG

11 fiscal years on record · EUR · FY2025 reported · SEC filings only

Revenue

€17.8B

▼ 1.0% YoY

Net income

€895.0M

In brief

What this company does

Koninklijke Philips N.V. provides integrated solutions that combine imaging systems and advanced clinical software, as well as diagnostic and therapeutic devices and services. Royal Philips' IP portfolio currently consists of approximately 53,000 patent rights, 31,500 trademarks, 159,000 design rights and 3,100 domain names. Its Diagnosis & Treatment business includes Precision Diagnosis, which offers a range of diagnostic imaging products, solutions and services. Its Connected Care business supports healthcare providers across hospital, ambulatory and home settings with advanced monitoring, diagnostics, informatics and sleep therapy solutions. Its Personal Health business enables individual care routines with technology and solutions that support people's long-term health and well-being.

Written from the business description in KONINKLIJKE PHILIPS NV's annual report to the U.S. Securities and Exchange Commission, filed 19 February 2026. Every sentence was checked against that document before publication.

Growth

EUR 17.8B

Revenue, FY2025 · full 11-year series below

Revenue €B Net income €B

FY2025 · Revenue 17.8 · Net income 0.9

Compound annual growth

Revenue

+0.0%

+0.6%

Net income

−5.5%

+3.7%

EPS, diluted

−6.3%

+3.2%

Dividend / share

+0.0%

+0.6%

3 yrs

5 yrs

10 yrs

15 yrs

Revenue compounded at +0.6% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

5 cents

of every revenue dollar became profit

Operating margin Net margin

FY2025 · Operating 8.0% · Net 5.0%

ROE

FY2025 · ROE 7.8%

Gross margin45.2%

Operating margin8.0%

Net margin5.0%

Return on assets3.2%

EBITDAEUR 2.5B

Each EUR of equity produced 8 cents of profit this year.

Cash & shareholders

—

returned in FY2025 · dividends + net buybacks

Net buybacks €B Dividends €B

FY2025 · Dividends — · Net buybacks -0.0

Dividends paid—

Net buybacksEUR -13.0M

Share of profit0.0%

Consecutive raises—

Total assetsEUR 26.9B

EquityEUR 11.0B

CashEUR 2.8B

Gross debtEUR 8.1B

Net debtEUR 5.3B

Current ratio1.32×

Net debt stands at 48% of equity.

The 11-year record

11 fiscal years

Every figure from documents filed with the SEC · EUR

row low → row highnegative

Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Revenue €B	17.8	18.0	18.2	17.8	17.2	17.3	17.1	18.1	17.8	17.4	16.8
Operating income €B	1.4	0.5	−0.1	−1.5	0.6	1.3	1.4	1.7	1.5	1.5	0.7
EBITDA €B	2.5	1.9	1.1	0.1	1.9	2.7	2.7	2.8	2.5	2.4	1.6
Income tax €B	0.3	1.0	−0.1	−0.1	−0.1	0.2	0.3	0.2	0.3	0.2	0.2
Net income €B	0.9	−0.7	−0.5	−1.6	3.3	1.2	1.2	1.1	1.7	1.4	0.6
EPS, diluted €	0.93	−0.75	−0.49	−1.69	3.50	1.29	1.25	1.14	1.75	1.56	0.68
Dividend / sh €	0.85	0.85	0.85	0.85	0.85	0.85	0.85	0.80	0.80	0.80	0.80
Payout %	·	·	−161	−46	23	64	39	37	45	51	48
ROE %	7.8	−5.8	−3.7	−11.6	25.2	9.7	9.5	9.1	13.5	12.0	5.4

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Compare

This company against its peers

Koninklijke Philips NVvsStevanato Group S.p.A.Same industry: X-Ray Apparatus & Tubes & Related Irradiation Apparatus Koninklijke Philips NVvsNyxoah SASame industry: X-Ray Apparatus & Tubes & Related Irradiation Apparatus

Provenance

Company facts, as filed

How we verify · 0 failures in 53 reconciliationsAUDITED

Reconciled in 11 of 19 fiscal years. 42 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures

ActivityX-Ray Apparatus & Tubes & Related Irradiation Apparatus

Listed onNYSE

Incorporated inoutside the United States — SEC code P7

Fiscal year endsDecember 31

Data on record since2015